Long-Term Outcome of Tofacitinib Treatment for Systemic Autoimmune Disease-Associated Refractory Scleritis.
Ocul Immunol Inflamm
; : 1-5, 2024 May 31.
Article
em En
| MEDLINE
| ID: mdl-38820228
ABSTRACT
PURPOSE:
To report the long-term outcome of three refractory anterior scleritis cases successfully treated with tofacitinib, a Janus-associated kinase inhibitor.METHODS:
Three patients with systemic autoimmune disease-associated anterior scleritis (two with rheumatoid arthritis and one with systemic lupus erythematosus), resistant to conventional immunomodulatory therapy, were subsequently treated with tofacitinib (10 mg/day).RESULTS:
Tofacitinib resulted in complete resolution of scleritis in all patients. During the 39-78 months of follow-up, no recurrence of scleritis occurred, and no adverse effects associated with tofacitinib were noted. At the last follow-up, all patients were free of scleritis with two patients receiving tofacitinib monotherapy and one without.CONCLUSION:
Tofacitinib can be a safe and effective treatment for noninfectious refractory scleritis, warranting further investigation in large clinical trials.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
Ocul Immunol Inflamm
Assunto da revista:
ALERGIA E IMUNOLOGIA
/
OFTALMOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article